Sanofi’s Generics Sales Stabilize Post-Zentiva
Emerging Markets Now Account For The Bulk Of Generics Turnover
Reporting its fourth-quarter and full-year 2019 results, Sanofi saw an overall drop in generics sales following 2018’s divestment of Zentiva in Europe but enjoyed consistent turnover in emerging markets. Moreover, fourth-quarter generics turnover showed a stabilization of the business once the Zentiva comparison is removed.
